VATIQUINONE


Synonyms	(R)-Alpha-Tocotrienol Quinone .alpha.-tocotrienol quinone Alpha tocotrienol quinone Alpha-tocotrienol quinone EPI-743 Vatiquinone
Status
Molecule Category	UNKNOWN
UNII	6O85FK9I0X
EPA CompTox	DTXSID90153231


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LNOVHERIIMJMDG-XZXLULOTSA-N
Smiles	CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O
InChI	InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C29H44O3
Molecular Weight	440.67
AlogP	7.52
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	12.0
Polar Surface Area	54.37
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	32.0

Bioactivity

Mechanism of Action	Action	Reference
Quinone reductase 1) modulator	MODULATOR	PubMed


Protein: Quinone reductase 1) Description: NAD(P)H dehydrogenase [quinone] 1 Organism : Homo sapiens P15559 ENSG00000181019

Assay Description	Organism	Bioactivity	Reference
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability	Homo sapiens	24.0 nM
Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Leigh syndrome patient fibroblasts assessed as increase of cell viability	Homo sapiens	30.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL1812161
DrugBank	DB11917
FDA SRS	6O85FK9I0X
PubChem	46184405
SureChEMBL	SCHEMBL503125

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).